Correction to: Naunyn-Schmiedeberg’s Arch Pharmacol (2015) 388:295–304
The Editor-in-Chief has retracted this article at the request of the first author. Concerns were raised regarding a number of figures in this article, specifically:
-
Figure 7a: the four right tumors of the Control group appear to be identical to the 5-Fu (20mg/kg) group of Figure 7a in [1]
-
Figure 8b: the lupeol (60mg/kg)/p-EGFR panel appears to partially overlap with the 5-FU (20mg/kg)/ p-AKT panel of Figure 8b in [1]
-
Figure 8c: the lupeol (60mg/kg)/MMP-9 panel appears to partially overlap with the 5-FU (20mg/kg)/p-ERK panel of Figure 8c in [1]
-
Figure 8d: the Control/PCNA panel appears to partially overlap with the Control/PCNA panel of Figure 8d in [1]
The first author has stated that some of the data could not be recovered. The Editor-in-Chief therefore no longer has confidence in the reliability of the data reported in the article.
All authors agree to this retraction.
[1] Liu, Y., Bi, T., Shen, G. et al. Lupeol induces apoptosis and inhibits invasion in gallbladder carcinoma GBC-SD cells by suppression of EGFR/MMP-9 signaling pathway. Cytotechnology 68, 123–133 (2016). https://doi.org/10.1007/s10616-014-9763-7
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1007/s00210-014-1071-4
About this article
Cite this article
Liu, Y., Bi, T., Wang, G. et al. Retraction Note to: Lupeol inhibits proliferation and induces apoptosis of human pancreatic cancer PCNA-1 cells through AKT/ERK pathways. Naunyn-Schmiedeberg's Arch Pharmacol 394, 1827 (2021). https://doi.org/10.1007/s00210-021-02113-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-021-02113-2